Contra-indicated in patients who have or have had progressive multifocal leukoencephalopathy.
Natalizumab-sztn (Tyruko) is biosimilar to Natalizumab (Tysabri). Approved 08/24/2023
- TRADE NAME: Tysabri (Biogen)
- INDICATIONS: Multiple sclerosis, Crohn's disease
- SYNONYM: antegren
- CLASS: Immunomodulator, Monoclonal antibody
- HALF-LIFE: 11 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Alefacept, Azacitidine, Azathioprine, Betamethasone, Cabazitaxel, Certolizumab, Cortocosteroids, Cyclosporine, Denileukin, Docetaxel, Fingolimod, Gefitinib, Leflunomide, Lenalidomide, Mercaptopurine, Methotrexate, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Rilonacept, Temsirolimus, Triamcinolone, Vedolizumab
- See adverse reactions attributed to class:
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of natalizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/29/2025
